Compare Cipla with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SANOFI INDIA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SANOFI INDIA CIPLA/
SANOFI INDIA
 
P/E (TTM) x 23.8 35.4 67.2% View Chart
P/BV x 2.4 6.2 39.2% View Chart
Dividend Yield % 0.7 1.4 47.0%  

Financials

 CIPLA   SANOFI INDIA
EQUITY SHARE DATA
    CIPLA
Mar-19
SANOFI INDIA
Dec-18
CIPLA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6786,840 9.9%   
Low Rs4844,630 10.4%   
Sales per share (Unadj.) Rs198.21,203.1 16.5%  
Earnings per share (Unadj.) Rs18.5165.3 11.2%  
Cash flow per share (Unadj.) Rs35.0209.9 16.7%  
Dividends per share (Unadj.) Rs3.0084.00 3.6%  
Dividend yield (eoy) %0.51.5 35.3%  
Book value per share (Unadj.) Rs186.3963.6 19.3%  
Shares outstanding (eoy) m805.7023.03 3,498.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.8 61.5%   
Avg P/E ratio x31.434.7 90.4%  
P/CF ratio (eoy) x16.627.3 60.8%  
Price / Book Value ratio x3.16.0 52.4%  
Dividend payout %16.250.8 31.9%   
Avg Mkt Cap Rs m468,031132,078 354.4%   
No. of employees `00022.63.3 686.0%   
Total wages/salary Rs m28,5654,068 702.2%   
Avg. sales/employee Rs Th7,053.18,393.8 84.0%   
Avg. wages/employee Rs Th1,261.51,232.4 102.4%   
Avg. net profit/employee Rs Th659.11,153.0 57.2%   
INCOME DATA
Net Sales Rs m159,71027,708 576.4%  
Other income Rs m4,766897 531.3%   
Total revenues Rs m164,47528,605 575.0%   
Gross profit Rs m30,9736,235 496.8%  
Depreciation Rs m13,2631,027 1,291.4%   
Interest Rs m1,6847 24,061.4%   
Profit before tax Rs m20,7916,098 341.0%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6952,292 248.5%   
Profit after tax Rs m14,9243,806 392.1%  
Gross profit margin %19.422.5 86.2%  
Effective tax rate %27.437.6 72.9%   
Net profit margin %9.313.7 68.0%  
BALANCE SHEET DATA
Current assets Rs m124,26615,922 780.5%   
Current liabilities Rs m37,7156,235 604.9%   
Net working cap to sales %54.235.0 155.0%  
Current ratio x3.32.6 129.0%  
Inventory Days Days9164 142.4%  
Debtors Days Days9521 454.6%  
Net fixed assets Rs m105,1907,539 1,395.3%   
Share capital Rs m1,611230 700.6%   
"Free" reserves Rs m148,51121,962 676.2%   
Net worth Rs m150,12322,192 676.5%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63329,839 803.1%  
Interest coverage x13.3872.1 1.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.9 71.8%   
Return on assets %6.912.8 54.2%  
Return on equity %9.917.2 58.0%  
Return on capital %11.827.5 43.0%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,4107,587 756.7%   
Fx outflow Rs m19,0417,145 266.5%   
Net fx Rs m38,368442 8,680.6%   
CASH FLOW
From Operations Rs m16,9113,739 452.3%  
From Investments Rs m-16,687-731 2,282.7%  
From Financial Activity Rs m-3,487-1,972 176.8%  
Net Cashflow Rs m-3,4511,036 -333.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 60.4 34.4%  
Indian inst/Mut Fund % 12.2 14.4 84.7%  
FIIs % 23.7 14.6 162.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 15,184 1,061.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DIVIS LABORATORIES  WOCKHARDT  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  UNICHEM LAB  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Climbs 975 Points Up; FMCG Stocks Fuel the Rally(09:30 am)

Asian share markets started higher on Monday on hopes of an interim Sino-US tariff deal after the two countries described their talks as "productive" and "constructive".

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 23, 2019 12:13 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS